BridgeBio Pharma’s $150 Million Common Stock Public Offering

Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved.BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of an…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Pietro Martinoia

This content is for Standard 1 Year members only.
Login Join Now